# BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

*PRI Rank #4 · Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026/rank-4*

| Field | Value |
| --- | --- |
| Rank | #4 |
| 18m citations | 74 |
| Journal | The Lancet Oncology |
| Year | 2024 |
| DOI | 10.1016/s1470-2045(24)00159-1 |
| Corresponding authors | Li Zhang, Hongyun Zhao |
| Institution | Sun Yat-sen University Cancer Center, China |

**Ranking page:** [Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026](https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026)

**Paper link:** [10.1016/s1470-2045(24)00159-1](https://doi.org/10.1016/s1470-2045(24)00159-1)

## Topics

BL-B01D1 · EGFR–HER3 bispecific antibody–drug conjugate · locally advanced solid tumours · Metastatic solid tumors · Phase I trial · Phase I trial · EGFR targeting · HER3 targeting · bispecific antibody · antibody-drug conjugate

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026. Accessed 2026-07-15.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```